Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05310344 | Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 50 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310357 | Chromosomal Instability in Ovarian Cancer | unknown | — | 300 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310370 |
| HRD and Resistance to PAPPi in EOC Patients |
| unknown |
| — |
| 400 |
| Lei LiOTHER |
| 1 |
| Apr 4, 2022 |
| clinicaltrials |
| NCT05259540 | Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma | unknown | Phase 2 | 42 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05290415 | Host DNA Methylation for Endometrial Cancer Screening | unknown | — | 10,000 | Lei LiOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290428 | DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening | unknown | — | 459 | Peking Union Medical College HospitalOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290922 | DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening | unknown | — | 7,150 | Lei LiOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290935 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial | unknown | Phase 2 | 122 | Lei LiOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05087264 | Clinical Study of Indocyanine Green Displaying Pelvic Nerve in Radical Operation of Cervical Cancer | unknown | Early Phase 1 | 86 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03976973 | BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei | unknown | Phase 2 | 62 | Mucpharm Pty LtdINDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT05274867 | Development of a Patient Reported Outcome Measure for Advanced Ovarian Cancer Patients Receiving Surgical and Chemotherapy Treatment(PROM-OSP) | unknown | — | 137 | The Christie NHS Foundation TrustOTHER | 0 | Mar 11, 2022 | clinicaltrials |
| NCT05273944 | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients | unknown | Phase 1 | 80 | Shenzhen Kangzhe Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT05270720 | Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer | unknown | Phase 1 | 9 | West China Second University HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03542669 | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | unknown | Phase 1 | 9 | Peking University People's HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03570437 | Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?(COPELIA) | unknown | Phase 2 | 124 | University of ManchesterOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05255861 | An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy | unknown | — | 300 | Xin WuOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT03955367 | Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer | unknown | Phase 3 | 638 | Peking Union Medical College HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05244811 | Treat of Functional Ovarian Cysts by Compare Between Cocs and Progesterone Only Pills | unknown | Phase 3 | 60 | Sohag UniversityOTHER | 0 | Feb 17, 2022 | clinicaltrials |
| NCT05236855 | Spectroscopy and Artificial Intelligence to Disrupt the Status Quo in Cervical Cancer Screening | unknown | — | 200 | IWK Health CentreOTHER | 0 | Feb 11, 2022 | clinicaltrials |
| NCT05234905 | H101 Combined With Camrelizumab for Recurrent Cervical Cancer | unknown | Phase 2 | 55 | Zhejiang Cancer HospitalOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05225493 | HIV Indicator Diseases in Hospital and Primary Care(#AwareHIV) | unknown | — | 1,500 | Erasmus Medical CenterOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05210348 | Clinical Evaluation of Detection of High Risk HPV in Urine(Urine-hrHPV) | unknown | — | 1,000 | Peking University People's HospitalOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05211557 | Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer | unknown | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05187208 | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer(POLO) | unknown | Phase 4 | 102 | Seoul National University HospitalOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT01042522 | Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors | unknown | Phase 2 | 63 | GOG FoundationNETWORK | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05174377 | CADx - Radiomics to Distinguish the Origin of Ovarian Tumors(CADx) | unknown | — | 600 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05185713 | The Mechanism of Vaginal Flora and Its Metabolites in the Pathogenesis of Cervical Cancer | unknown | — | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05175326 | Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs | unknown | — | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT04371887 | Comparing Strategies for Implementing Primary HPV Screening | unknown | N/A | 45,000 | Chun ChaoOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT01595061 | Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva | unknown | Phase 2 | 57 | Gynecologic Oncology GroupNETWORK | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05105672 | A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05170594 | A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer | unknown | Phase 2 | 60 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05167149 | Carbon Nanoparticles and Indocyanine Green for Sentinel Lymph Node Biopsy in Early Stage Cervical Cancer | unknown | N/A | 144 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT04375956 | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients(MITO 27) | unknown | Phase 2 | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT03668639 | Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin | unknown | Phase 2 / Phase 3 | 80 | Christina RuhlmannOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05068921 | A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05059015 | Human Papilloma Virus (HPV) Self-collection and Women Adherence | unknown | N/A | 80 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Dec 10, 2021 | clinicaltrials |
| NCT05153603 | Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting | unknown | — | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Dec 10, 2021 | clinicaltrials |
| NCT05150262 | Urinary Procedures Performed by Gynecologists, Results and Learning Curves.(URINA) | unknown | — | 96 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05151549 | A Study of Carilizumab Combined With Concurrent Chemoradiotherapy | unknown | Phase 2 | 46 | Hunan Cancer HospitalOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT05145218 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer | unknown | Phase 3 | 405 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05146505 | miRNAs in High Grade Serous Ovarian Cancer(MIROC) | unknown | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT04620954 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-02) | unknown | Phase 1 / Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT05121363 | A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma | unknown | Phase 2 | 113 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05137171 | AK105 Combined With Anlotinib in Patients With Cervical Cancer | unknown | Phase 2 | 36 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Nov 30, 2021 | clinicaltrials |
| NCT04443296 | Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma(TIL-Cx) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT04934982 | Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)(LAUNCH 1) | unknown | N/A | 690 | Hua JiangOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT04939831 | Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB3,IIA2)(LAUNCH 3) | unknown | N/A | 1,104 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Nov 10, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Apr 4, 2022source: clinicaltrials